4
Participants
Start Date
June 30, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Cabazitaxel plus bavituximab
Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
Medical University of South Carolina, Charleston
Collaborators (1)
Peregrine Pharmaceuticals
INDUSTRY
Medical University of South Carolina
OTHER